Pathogenesis of hiv-associated pulmonary hypertension: Potential role of HIV-1 nef

Proceedings of the American Thoracic Society

Volumn 8, Issue 3, 2011, Pages 308-312

  Almodovar, Sharilyn ^a   Hsue, Priscilla Y ^b   Morelli, Julie ^b   Huang, Laurence ^c   Flores, Sonia C ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

HIV proteins; HIV 1 Nef; Lung HIV study; Pathogenesis; Pulmonary hypertension

Indexed keywords

ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; NEF PROTEIN; TRANSACTIVATOR PROTEIN;

CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DISEASE ASSOCIATION; DOPPLER ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; GENE MUTATION; HEART CATHETERIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PATHOGENESIS; PROGNOSIS; PULMONARY HYPERTENSION; SIMIAN IMMUNODEFICIENCY VIRUS; THORAX RADIOGRAPHY;

DOWN-REGULATION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ENDOTHELIUM; FEMALE; GENETIC MARKERS; HEART CATHETERIZATION; HIV INFECTIONS; HUMANS; HYPERTENSION, PULMONARY; LUNG; MALE; MIDDLE AGED; MUTATION; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PROTEIN MULTIMERIZATION; PROTEIN TRANSPORT; SEQUENCE ANALYSIS, PROTEIN; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 80051709372     PISSN: 15463222     EISSN: 19435665     Source Type: Journal    
DOI: 10.1513/pats.201006-046WR     Document Type: Conference Paper

References (42)

1. Joint United Nations Program on HIV/AIDS and World Health Organization. Global Report: UNAIDS report on the global AIDS epidemic 2010 (accessed March 2011). Available from: http://www.unaids.org.
2. Braithwaite RS, Justice AC, Chang CC, Fusco JS, Raffanti SR, Wong JB, Roberts MS. Estimating the proportion of patients infected with HIV who will die of comorbid diseases. Am J Med 2005;118:890-898. (Pubitemid 41097468)
3. Krentz HB, Kliewer G, Gill MJ. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. HIV Med 2005;6:99-106. (Pubitemid 40425973)
4. Crum NF, Riffenburgh RH, Wegner S, Agan BK, Tasker SA, Spooner KM, Armstrong AW, Fraser S, Wallace MR. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr 2006;41:194-200.
5. Diaz PT, King MA, Pacht ER, Wewers MD, Gadek JE, Nagaraja HN, Drake J, Clanton TL. Increased susceptibility to pulmonary emphysema among HIV-seropositive smokers. Ann Intern Med 2000;132:369-372. (Pubitemid 30127775)
6. Crothers K, Butt AA, Gibert CL, Rodriguez-Barradas MC, Crystal S, Justice AC. Increased COPD among HIV-positive compared to HIV-negative veterans. Chest 2006;130:1326-1333. (Pubitemid 44786723)
7. Kirk GD, Merlo C, O' Driscoll P, Mehta SH, Galai N, Vlahov D, Samet J, Engels EA. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis 2007;45:103-110. (Pubitemid 46984625)
8. Mehta NJ, Khan IA, Mehta RN, Sepkowitz DA. HIV-related pulmonary hypertension: analytic review of 131 cases. Chest 2000;118:1133-1141.
9. Opravil M, Sereni D. Natural history of HIV-associated pulmonary arterial hypertension: trends in the HAART era. AIDS 2008;22:S35-S40.
10. Degano B, Guillaume M, Savale L, Montani D, Jais X, Yaici A, Le PJ, Humbert M, Simonneau G, Sitbon O. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. AIDS 2010;24:67-75.
11. Malek J, Rogers R, Kufera J, Hirshon JM. Venous thromboembolic disease in the HIV-infected patient. Am J Emerg Med 2011;29:278-282.
12. Humbert M. Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology. Eur Respir Rev 2010;19:59-63.
13. Badesch DB, Champion HC, Sanchez MA, Hoeper MM, Loyd JE, Manes A, McGoon M, Naeije R, Olschewski H, Oudiz RJ, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:S55-S66.
14. Nunes H, Humbert M, Sitbon O, Morse JH, Deng Z, Knowles JA, Le Gall C, Parent F, Garcia G, Herve P, et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2003;167:1433-1439. (Pubitemid 36609730)
15. Galie N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, Olschewski H, Peacock A, Pietra G, Rubin LJ, et al. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Eur Heart J 2004;25:2243-2278.
16. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007;131:1917-1928. (Pubitemid 46981654)
17. Merry C, Barry MG, Ryan M, Tjia JF, Hennessy M, Eagling VA, Mulcahy F, Back DJ. Interaction of sildenafil and indinavir when coad-ministered to HIV-positive patients. AIDS 1999;13:F101-F107. (Pubitemid 29509575)
18. Muirhead GJ, Wulff MB, Fielding A, Kleinermans D, Buss N. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol 2000;50:99-107. (Pubitemid 30612027)
19. Marecki JC, Cool CD, Parr JE, Beckey VE, Luciw PA, Tarantal AF, Carville A, Shannon RP, Cota-Gomez A, Tuder RM, et al. HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques. Am J Respir Crit Care Med 2006;174:437-445. (Pubitemid 44223125)
20. Petitpretz P, Brenot F, Azarian R, Parent F, Rain B, Herve P, Simonneau G. Pulmonary hypertension in patients with human immunodeficiency virus infection: comparison with primary pulmonary hypertension. Circulation 1994;89:2722-2727. (Pubitemid 24173693)
21. Bruce-Keller AJ, Barger SW, Moss NI, Pham JT, Keller JN, Nath A. Pro-inflammatory and pro-oxidant properties of the HIV protein Tat in a microglial cell line: attenuation by 17 beta-estradiol. J Neurochem 2001;78:1315-1324. (Pubitemid 32899763)
22. Lehmann MH, Walter S, Ylisastigui L, Striebel F, Ovod V, Geyer M, Gluckman JC, Erfle V. Extracellular HIV-1 Nef increases migration of monocytes. Exp Cell Res 2006;312:3659-3668. (Pubitemid 44470783)
23. Alexander L, Weiskopf E, Greenough TC, Gaddis NC, Auerbach MR, Malim MH, O'Brien SJ, Walker BD, Sullivan JL, Desrosiers RC. Unusual polymorphisms in human immunodeficiency virus type 1 associated with nonprogressive infection. J Virol 2000;74:4361-4376. (Pubitemid 30214444)
24. Albini A, Ferrini S, Benelli R, Sforzini S, Giunciuglio D, Aluigi MG, Proudfoot AE, Alouani S, Wells TN, Mariani G, et al. HIV-1 Tat protein mimicry of chemokines. 1. Proc Natl Acad Sci USA 1998;95:13153-13158. (Pubitemid 28509540)
25. Cota-Gomez A, Flores NC, Cruz C, Casullo A, Aw TY, Ichikawa H, Schaack J, Scheinman R, Flores SC. The human immunodeficiency virus-1 Tat protein activates human umbilical vein endothelial cell Eselectin expression via an NF-kappa B-dependent mechanism. J Biol Chem 2002;277:14390-14399. (Pubitemid 34952502)
26. Westhorpe CL, Zhou J, Webster NL, Kalionis B, Lewin SR, Jaworowski A, Muller WA, Crowe SM. Effects of HIV-1 infection in vitro on transendothelial migration by monocytes and monocyte-derived macrophages. J Leukoc Biol 2009;85:1027-1035.
27. Hsue PY, Deeks SG, Farah HH, Palav S, Ahmed SY, Schnell A, Ellman AB, Huang L, Dollard SC, Martin JN. Role of HIV and human herpesvirus-8 infection in pulmonary arterial hypertension. AIDS 2008;22:825-833. (Pubitemid 351563831)
28. Montani D, Marcelin AG, Sitbon O, Calvez V, Simonneau G, Humbert M. Human herpes virus 8 in HIV and non-HIV infected patients with pulmonary arterial hypertension in France. AIDS 2005;19:1239-1240. (Pubitemid 41059271)
29. Kanmogne GD, Primeaux C, Grammas P. Induction of apoptosis and endothelin-1 secretion in primary human lung endothelial cells by HIV-1 gp120 proteins. Biochem Biophys Res Commun 2005;333:1107-1115. (Pubitemid 40910118)
30. Rusnati M, Presta M. HIV-1 Tat protein and endothelium: from protein/cell interaction to AIDS-associated pathologies. Angiogenesis 2002;5:141-151. (Pubitemid 36687517)
31. Kim J, Ruff M, Karwatowska-Prokopczuk E, Hunt L, Ji H, Pert CB, Zukowska-Grojec Z. HIV envelope protein gp120 induces neuropeptide Y receptor-mediated proliferation of vascular smooth muscle cells: relevance to AIDS cardiovascular pathogenesis. Regul Pept 1998;75-76:201-205. (Pubitemid 28477528)
32. Albini A, Barillari G, Benelli R, Gallo RC, Ensoli B. Angiogenic properties of human immunodeficiency virus type 1 Tat protein. Proc Natl Acad Sci USA 1995;92:4838-4842.
33. Albini A, Soldi R, Giunciuglio D, Giraudo E, Benelli R, Primo L, Noonan D, Salio M, Camussi G, Rockl W, et al. The angiogenesis induced by HIV-1 Tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells. Nat Med 1996;2:1371-1375. (Pubitemid 26401742)
34. Roeth JF, Collins KL. Human immunodeficiency virus type 1 Nef: adapting to intracellular trafficking pathways. Microbiol Mol Biol Rev 2006;70:548-563. (Pubitemid 43895037)
35. Sehgal PB, Mukhopadhyay S, Patel K, Xu F, Almodovar S, Tuder RM, Flores SC. Golgi dysfunction is a common feature in idiopathic human pulmonary hypertension and vascular lesions in SHIV-nef-infected macaques. Am J Physiol Lung Cell Mol Physiol 2009;297:L729-L737.
36. Chaudhry A, Verghese DA, Das SR, Jameel S, George A, Bal V, Mayor S, Rath S. HIV-1 Nef promotes endocytosis of cell surface MHC class II molecules via a constitutive pathway. J Immunol 2009;183:2415-2424.
37. Poe JA, Smithgall TE. HIV-1 Nef dimerization is required for Nef-mediated receptor downregulation and viral replication. J Mol Biol 2009;394:329-342.
38. Lenassi M, Cagney G, Liao M, Vaupotic T, Bartholomeeusen K, Cheng Y, Krogan NJ, Plemenitas A, Peterlin BM. HIV Nef is secreted in exosomes and triggers apoptosis in bystander CD4+ T cells. Traffic 2010;11:110-122.
39. Nobile C, Rudnicka D, Hasan M, Aulner N, Porrot F, Machu C, Renaud O, Prevost MC, Hivroz C, Schwartz O, et al. HIV-1 Nef inhibits ruffles, induces filopodia, and modulates migration of infected lymphocytes. J Virol 2010;84:2282-2293.
40. Park IW, He JJ. HIV-1 Nef-mediated inhibition of T cell migration and its molecular determinants. J Leukoc Biol 2009;86:1171-1178.
41. Geyer M, Fackler OT, Peterlin BM. Structure - function relationships in HIV-1 Nef. EMBO Rep 2001;2:580-585. (Pubitemid 32707703)
42. Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp Ser 1999;41:95-98.